




Searching News Database: Medivation
HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
HSMN NewsFeed - 12 Feb 2018
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 3 Jan 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
HSMN NewsFeed - 26 Sep 2016
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
HSMN NewsFeed - 10 Aug 2015
Aratana Therapeutics Elects Wendy Yarno as Chairman of the Board of Directors
Aratana Therapeutics Elects Wendy Yarno as Chairman of the Board of Directors
HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
HSMN NewsFeed - 16 Mar 2012
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
HSMN NewsFeed - 28 Feb 2006
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
Additional items found! 8

Members Archive contains
8 additional stories matching:
Medivation
(Password required)
Medivation
(Password required)